Ukuhlolwa Okusha Komtholampilo Kwe-Metastatic Castration-Resistant Prostate Cancer

January 20, 2022
by umhleli
Engeza amazwana
I-3 min ifunde
en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
Ibhalwe ngu umhleli

I-ESSA Pharma Inc., inkampani eyenza imithi esezingeni lomtholampilo egxile ekuthuthukiseni izindlela zokwelapha ezintsha zokwelapha umdlavuza wendlala yesinye, namuhla imemezele isiguli sokuqala esifakwe ocwaningweni oluxhaswe yiNkampani lweSigaba 1/2 ukuze kuhlolwe ukuphepha, ukubekezelelana nokusebenza kahle kwe-ESSA's. ikhandidethi lomkhiqizo ophambili, i-EPI-7386, i-N-terminal domain androgen receptor inhibitor yokuqala esigabeni sokuqala, ihlanganiswe ne-Astellas Pharma Inc.'s kanye ne-Pfizer Inc.'s ehlanganisa i-androgen receptor inhibitor, i- enzalutamide, ezigulini ezine- i-metastatic castration-resistant prostate cancer.

Phrinta Friendly, PDF & Imeyili

“Ukuqaliswa kwalolu cwaningo oluyinhlanganisela no-Astellas kuwumzuzu wamanzi we-ESSA njengoba siphenya inzuzo yomtholampilo engaba khona yokuvimbela i-androgen receptor ngokusebenzisa izindlela ezimbili ezizimele ekwelapheni iziguli ezine-mCRPC ezingakatholi ukwelashwa nge-antiandrogen yesizukulwane sesibili. izidakamizwa,” kusho uDkt. David. R. Parkinson, Isikhulu Esiphezulu, i-ESSA Pharma Inc. “Ukuhlanganisa izindlela zethu zokwelapha ezimbili kuzoqondisa ngesikhathi esisodwa iziphetho zombili zesamukeli se-androgen. Kumamodeli we-preclinical, sibonile ukuthi ukuhlanganisa i-EPI-7386 nama-antiandrogens amanje kungaholela ekuvinjweni okujulile nokubanzi kwe-androgen biology. Lesi sivivinyo seSigaba 1/2 siphawula okokuqala ochungechungeni lwezifundo zomtholampilo ukuhlola i-EPI-7386 kuhlanganiswe nemithi yamanje ye-antiandrogen ezigulini ezine-mCRPC, nokuhlolwa okwengeziwe kwenhlanganisela yeSigaba 1/2 okulindeleke ukuthi kuqale ngo-2022.

Uhlolo lomtholampilo lweSigaba 1/2 (NCT05075577) luqala ngengxenye yesigaba sokuqala lapho kulungiswa imithamo yomuthi ngamunye kulandelwa ingxenye yesigaba 1 lapho i-ejenti eyodwa enzalutamide iqhathaniswa nenhlanganisela ye- enzalutamide ne-EPI-2. Ucwaningo lwesigaba 7386 kulindeleke ukuthi lubhalise iziguli ezifika ku-1 ​​mCRPC ezingakaphathwa ngemithi yokwelapha ye-antiandrogen yesizukulwane sesibili. Umgomo wengxenye yesigaba 30 socwaningo ukuhlola ukuphepha nokubekezeleleka kwenhlanganisela yomuthi nokusungula imithamo enconyiwe yesigaba 1 ye-EPI-2 kanye ne enzalutamide lapho imithamo ihlanganiswa. Ucwaningo lwesigaba 7386 kulindeleke ukuthi lubhalise iziguli ze-2 mCRPC ezingakaphathwa ngemithi yokwelapha ye-antiandrogen yesizukulwane sesibili. Umgomo wesigaba sesi-120 sengxenye yocwaningo ukuhlola ukuphepha, ukubekezelelana nomsebenzi we-EPI-2 wokulwa nesimila kuhlanganiswe nomthamo ongashintshi we enzalutamide uma kuqhathaniswa ne- enzalutamide njenge-ejenti eyodwa.

Phrinta Friendly, PDF & Imeyili

Kukhona Ongakuthanda

Mayelana umbhali

umhleli

Umhleli omkhulu we-eTurboNew nguLinda Hohnholz. Uzinze e-eTN HQ e-Honolulu, e-Hawaii.

Buka konke okuthunyelwe

Shiya amazwana

eTurboNews | eTN